Clinical trials: Hyperlipoproteinemia
Diabetes, Hyperlipidemia
Expanding Comparative Effectiveness Research (CER) Capability Through Complex Patient Relationship Management
The investigators are testing whether patients with diabetes can communicate with our health care system through text messaging.
- Trial name
- NCT01391585
- Testing
- Text Message prompts
- Where
- United States
- Volunteers
- 135 people
- Sponsor
- Denver Health and Hospital Authority
Hyperlipidemia
Comparison of the Combination of Fenofibrate and Simvastatin Versus Atorvastatin
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia.
- Trial name
- NCT00362934
- Testing
- fenofibrate / simvastatin, Atorvastatin
- Where
- 68 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 516 people
- Sponsor
- Solvay Pharmaceuticals
Homozygous Familial Hypercholesterolemia
The Rogosin Institute Homozygous Familial Hypercholesterolemia Repository
This repository will establish for the first time a system to carefully assess and monitor over time the general health and the amount of cholesterol in the arteries of U.S.
- Trial name
- NCT01109368
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- The Rogosin Institute
Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
The objective of this study is to evaluate the efficacy and tolerability of adding anacetrapib to ongoing statin therapy in participants with heterozygous familial hypercholesterolemia (HeFH).
- Trial name
- REALIZE (NCT01524289)
- Testing
- Anacetrapib
- Volunteers
- 306 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiovascular Diseases, Coronary Disease
Hyperapo B and Coronary Heart Disease
To determine the role of apolipoprotein B and apolipoprotein A1 in the etiology of coronary artery disease.
- Conditions
- Cardiovascular Diseases, Coronary Disease, Heart Diseases, Diabetes Mellitus
- Trial name
- NCT00005168
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Healthy
A Study to Assess Any Potential Interaction Between Colesevelam and Ciclosporin in Healthy Volunteers
This study is designed to assess any potential interaction between colesevelam and ciclosporin in healthy volunteers.
- Trial name
- NCT00692250
- Testing
- Colesevelam hydrochloride film-coated tablets (Cholestagel)
- Where
- Netherlands
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Type 2 Diabetes Mellitus, Obesity
RCT Examining Effects of Probiotics in T2DM Individuals
Background: The connection between gut health and diabetes status is increasingly recognized. Gut microbiota composition in diabetic differs from non-diabetic individuals.
- Conditions
- Type 2 Diabetes Mellitus, Obesity, Hypertension, Hyperlipidemia
- Trial name
- NCT01752803
- Testing
- Probiotic
- Where
- Malaysia
- Volunteers
- 100 people
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
Hyperlipidemia
Telephone Based Management of Hyperlipidemia
The purpose of the study is to demonstrate that systematic self measurement of blood lipids reduces LDL cholesterol more effectively than standard care.
- Trial name
- NCT01212159
- Testing
- Self Monitoring Lipid Analyzer
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Temple University
Type 2 Diabetes Mellitus, Hypertension
Vitamin D and Omega-3 Inhibit Metabolic Syndrome
The study will test the hypothesis that supplementing the diet of subjects with Metabolic Syndrome with 2000 IU vitamin D and 1.8 g omega-3 fatty acids (EPA + DHA) per day, will facilitate weight loss, improve body composition…
- Conditions
- Type 2 Diabetes Mellitus, Hypertension, Hyperlipidemia, Obesity
- Trial name
- NCT01326442
- Testing
- low glycemic diet, vitamin D omega-3
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Guelph
Osteoporosis, Cardiovascular Diseases
Effect of Soy Bread on Markers of Bone Metabolism and Cardiovascular Disease
A study was designed with two specific aims: (1) to assess the effect of soy bread, compared with wheat bread, on markers of bone metabolism and cardiovascular health, and (2) to evaluate whether soy bread consumption affects the…
- Trial name
- NCT00366860
- Testing
- Soy bread
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Cardiovascular Risk Factors, Cardiovascular Diseases
Management of Cardiovascular Risk Factors
This practical experience should report a retrospective collection of data regarding cardiovascular risk factors of cardiovascular diseases.
- Trial name
- NCT00848380
- Where
- 36 sites in Switzerland
- Volunteers
- 1,492 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hypertension, Hyperlipidemia
Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia
To evaluate the safety and efficacy of CJ-30061 compared with amlodipine/valsartan combination therapy and valsartan/atorvastatin combination therapy in hypertensive patients with hyperlipidemia
- Trial name
- NCT03639480
- Testing
- Amlodipine 10mg+Valsartan 160mg+Atorvastatin 40mg, Amlodipine 10mg+Valsartan 160mg, Valsartan 160mg+Atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- HK inno.N Corporation
Non-Alcoholic Fatty Liver Disease
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients
A double-blind placebo controlled randomized Phase 3 study to evaluate the safety and tolerability of once-daily, oral administration of 80 or 100 mg resmetirom versus matching placebo.
- Trial name
- MAESTRO-NAFLD1 (NCT04197479)
- Testing
- Resmetirom
- Where
- 77 sites in United States, Puerto Rico
- Volunteers
- 1,343 people
- Sponsor
- Madrigal Pharmaceuticals, Inc.
Hypercholesterolemia, Hyperlipidemia
Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels
The objective of this study is to determine if the administration of a cholesterol lowering drug like ezetimibe will reduce circulating omega-3 fatty acid (ALA) levels in patients with heart disease and hypercholesterolemia.
- Trial name
- NCT00955227
- Testing
- Flax seed oil (ALA), Ezetimibe
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- University of Manitoba
Familial Hypercholesterolaemia, Hypercholesterolaemia
Specified Drug-use Survey of Leqvio for s.c. Injection.
The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical practice
- Trial name
- NCT06275724
- Testing
- inclisiran
- Where
- 107 sites in Japan
- Volunteers
- 585 people
- Sponsor
- Novartis Pharmaceuticals
Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Recessive
Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis
This pilot study investigates integrating whole genome sequencing and digital twin technology for managing hypercholesterolemia in Abu Dhabi clinics.
- Conditions
- Hypercholesterolemia, Autosomal Dominant, Hypercholesterolemia, Autosomal Recessive, Familial Combined Hypercholesterolemia
- Trial name
- NCT06535542
- Testing
- Whole Genome Sequencing
- Where
- United Arab Emirates
- Volunteers
- 40 people
- Sponsor
- Abu Dhabi Health Services Company
Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
The purpose of this study is to evaluate the safety and efficacy of mipomersen (ISIS 301012) in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy.
- Conditions
- Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases
- Trial name
- RADICHOL 1 (NCT00607373)
- Testing
- mipomersen
- Where
- 10 sites in United States, Brazil and 5 more
- Volunteers
- 51 people
- Sponsor
- Kastle Therapeutics, LLC
Familial Dysbetalipoproteinemia, Hyperlipoproteinemia Type III
Effects of Evolocumab Versus Placebo Added to Standard Lipid-lowering Therapy on Fasting and Post Fat Load Lipids in Patients With Familial Dysbetalipoproteinemia
Patients with familial dysbetalipoproteinemia (FD) have increased triglycerides, non-high-density lipoprotein cholesterol (non-HDL-C), beta VLDL, premature atherosclerosis and cardiovascular disease.
- Trial name
- EVOLVE-FD (NCT03811223)
- Testing
- Evolocumab Auto-Injector [Repatha]
- Volunteers
- 30 people
- Sponsor
- UMC Utrecht
Hyperlipidemia
Development and Clinical Validation of Key Technologies for Non-invasive Breath Metabolic Fingerprinting for Large-scale Population Lipid Screening
This study collects exhaled breath condensate samples from healthy populations and hyperlipidemic populations, analyzes the characteristics of the exhaled metabolic lipid profile for early identification of people with abnormal…
- Trial name
- NCT07546162
- Testing
- Lipid Abnormality Mass Spectrometry Screening Model
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Beijing Anzhen Hospital
Overweight and Obesity, NAFLD
Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects
The primary objective of this study is to evaluate the safety, tolerability and compare the pharmacokinetic parameters of ASC41, a THR beta agonist tables in overweight and obese subjects who have elevated LDL-C .
- Conditions
- Overweight and Obesity, NAFLD, Hyperlipidemia
- Trial name
- NCT04686994
- Testing
- ASC 41
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gannex Pharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.